Margin performance in line with expectations: Jonathan Hunt, Syngene

"Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufacture under licence from Gilead. That, of course, gave an additional boost in the quarter."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3y7OgjU
via IFTTT